Synonyms
Definition
C-type natriuretic peptide (CNP) is a paracrine/autocrine peptide belonging to the family of natriuretic peptides. All natriuretic peptides share a structurally related C-terminus that constitutes the receptor-binding site in the molecules. The intracellular signaling of CNP is mediated through a specific CNP receptor, e.g., natriuretic peptide receptor B (NPR-B) as well as via the common natriuretic peptide receptor C (NPR-C), which acts both as a clearance receptor and as a trigger of intracellular signaling. CNP is synthesized in many tissues and cell types, and the CNP system accordingly plays a role in several physiological processes – including bone growth and vascular homeostasis. Different targets of the CNP system have been in recent focus for drug development, and these pharmacological interventions have shown a promising clinical potential.
Basic Characteristics
C-Type Natriuretic Peptides
In 1990, C-type natriuretic...
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Breinholt VM, Rasmussen CE, Mygind PH et al (2019) Transcon CNP, a sustained-release C-type natriuretic peptide prodrug, a potentially safe and efficacious new therapeutic modality for the treatment of comorbidities associated with fibroblast growth factor receptor 3-related skeletal dysplasias. J Pharmacol Exp Ther. https://doi.org/10.1124/jpet.119.258251
Egom EE, Feridooni T, Pharithi RB et al (2017) A natriuretic peptides clearance receptor’s agonist reduces pulmonary artery pressures and enhances cardiac performance in preclinical models: new hope for patients with pulmonary hypertension due to left ventricular heart failure. Biomed Pharmacother. https://doi.org/10.1016/j.biopha.2017.07.027
Kawakami R, Lee CYW, Scott C et al (2018) A human study to evaluate safety, tolerability, and cyclic GMP activating properties of Cenderitide in subjects with stable chronic heart failure. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.974
Legeai-Mallet L (2016) C-type natriuretic peptide analog as therapy for achondroplasia. Endocr. Dev. 30:98–105Â
Lippert S, Goetze JP (2010) C-type natriuretic-derived peptides as biomarkers in human disease. Biomark. Med. 4:631–639
Lippert SK, Rehfeld JF, Goetze JP (2010) Processing-independent analysis for pro-C-type natriuretic peptide. J Immunol Methods. https://doi.org/10.1016/j.jim.2010.08.003
Lok DJ, Klip IT, Voors AA et al (2014) Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Fail. https://doi.org/10.1002/ejhf.140
McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. https://doi.org/10.1056/NEJMoa1409077
Mirczuk, Lessey, Catterick, et al (2019) Regulation and function of C-type natriuretic peptide (CNP) in gonadotrope-derived cell lines. Cell https://doi.org/10.3390/cells8091086
Moyes AJ, Hobbs AJ (2019) C-type natriuretic peptide: a multifaceted paracrine regulator in the heart and vasculature. Int J Mol Sci. https://doi.org/10.3390/ijms20092281
Moyes AJ, Chu SM, Aubdool AA et al (2019) C-type natriuretic peptide co-ordinates cardiac structure and function. Eur Heart J. https://doi.org/10.1093/eurheartj/ehz093
Pemberton CJ, Siriwardena M, Kleffmann T, Richards AM (2014) C-type natriuretic peptide (CNP) signal peptide fragments are present in the human circulation. Biochem Biophys Res Commun. https://doi.org/10.1016/j.bbrc.2014.05.020
Potter LR (2011) Natriuretic peptide metabolism, clearance and degradation. FEBS J. 278:1808–1817
Prickett TCR, Espiner EA (2012) C-type natriuretic peptide (CNP) and postnatal linear growth. In: Handbook of Growth and Growth Monitoring in Health and Disease. pp 2789–2809
Prickett TCR, Olney RC, Cameron VA et al (2013) Impact of age, phenotype and cardio-renal function on plasma C-type and B-type natriuretic peptide forms in an adult population. Clin Endocrinol. https://doi.org/10.1111/cen.12035
Prickett TCR, Doughty RN, Troughton RW et al (2017) C-type natriuretic peptides in coronary disease. Clin Chem. https://doi.org/10.1373/clinchem.2016.257816
Savarirayan R, Irving M, Bacino CA et al (2019) C-type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med. https://doi.org/10.1056/NEJMoa1813446
Sellitti DF, Koles N, Mendona MC (2011) Regulation of C-type natriuretic peptide expression. Peptides 32:1964–1971
Singh G, Maguire JJ, Kuc RE et al (2006) Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation. Br J Pharmacol. https://doi.org/10.1038/sj.bjp.0706924
Solomon SD, McMurray JJV, Anand IS et al (2019) Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. https://doi.org/10.1056/NEJMoa1908655
Takei Y (1999) Structural and functional evolution of the natriuretic peptide system in vertebrates. Int. Rev. Cytol. 194:1–66Â
Walther T, Stepan H (2004) C-type natriuretic peptide in reproduction, pregnancy and fetal development. J. Endocrinol. 180:17–22
Zois NE, Bartels ED, Hunter I, et al (2014) Natriuretic peptides in cardiometabolic regulation and disease. Nat. Rev. Cardiol. 11:403–412
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Mark, P.D., Goetze, J.P. (2021). C-Type Natriuretic Peptide and Its Receptors. In: Offermanns, S., Rosenthal, W. (eds) Encyclopedia of Molecular Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-030-57401-7_6235
Download citation
DOI: https://doi.org/10.1007/978-3-030-57401-7_6235
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-57400-0
Online ISBN: 978-3-030-57401-7
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences